PositiveID (PositiveID) ROCE % : 0.00% (As of Mar. 2018)

View and export this data going back to 2007. Start your Free Trial

What is PositiveID ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PositiveID's annualized ROCE % for the quarter that ended in Mar. 2018 was 0.00%.

PositiveID ROCE % Historical Data

The historical data trend for PositiveID's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID ROCE % Chart

PositiveID Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

ROCE %

Get a 7-Day Free Trial

PositiveID Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

PositiveID ROCE % Calculation

PositiveID's annualized ROCE % for the fiscal year that ended in Dec. 2017 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	-5.02	/	( ( (2.562 - 11.407)	+	(1.725 - 11.418) )	/ 2 )
	=	-5.02	/	( (-8.845	+	-9.693)	/ 2 )
	=	-5.02	/	-9.269
	=	54.16 %

PositiveID's ROCE % of for the quarter that ended in Mar. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2018 )		(Q: Dec. 2017 )		(Q: Mar. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2018 )		(Q: Dec. 2017 )		(Q: Mar. 2018 )
	=	-8.54	/	( ( (1.725 - 11.418)	+	(1.213 - 11.922) )	/ 2 )
	=	-8.54	/	( ( -9.693	+	-10.709 )	/ 2 )
	=	-8.54	/	-10.201
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

PositiveID (OTCPK:PSID) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PositiveID ROCE % Related Terms

Thank you for viewing the detailed overview of PositiveID's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PositiveID (PositiveID) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445

Website

http://www.psidcorp.com

PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.

Executives

Ned L Siegel	director	600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz	director	1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein	director	1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman	other: Former 10% Owner
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K	director	2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105